Work

Combination Therapies for HPV-Associated Malignancies.

Year: 2021

Type: article

Abstract: Human papillomavirus (HPV)-associated malignancies cause almost all cases of cervical cancer in women, and a significant percentage of head and neck cancer, together totaling almost 5% of the global cancer burden, and representing an important public health issue. The approval and use of two prophylactic HPV vaccines, Gardasil® and Cervarix®, have significantly decreased infections with HPV, but unfortunately, prophylactic vaccination does not treat established infections or malignancies resulting from HPV. Therefore, therapies for HPV-associated malignancies are necessary to improve the quality of life and survival in patients with these diseases. This review will detail new combinations of therapies in clinical development for HPV-associated malignancies.

Source: PubMed

Authors: Claire Smalley Rumfield, Jeffrey Schlom, Caroline Jochems

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Cervical Cancer and HPV Research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Strategies for Cancer Immunotherapy Development: Preclinical Studies